Quest Diagnostics Incorporated
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James E. Davis
- Full Time Employees
- 55,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 500 Plaza Drive Secaucus NJ United States of America 07094
- IPO Date
- Dec 17, 1996
- CIK
- 0001022079
- Website
- questdiagnostics.com
- Similar Companies
- Business
- Quest Diagnostics Incorporated (NYSE: DGX) provides diagnostic information services, including routine, non-routine, and advanced clinical laboratory testing; anatomic pathology testing; and related healthcare insights derived from one of the world's largest clinical lab databases. The company offers an industry-leading menu of tests across specialties such as endocrinology, immunology, neurology, oncology, infectious diseases (including COVID-19 molecular and serology testing, tuberculosis via T-SPOT.TB and Quantiferon, and tick-borne diseases via Accutix), drug monitoring and toxicology (as the largest U.S. workplace drug testing provider for urine, hair, and oral fluid specimens), cardiovascular diagnostics through its CardioIQ and Cleveland HeartLab offerings at the Cardiometabolic Center of Excellence, and cancer diagnostics via QuestVantage; it also delivers employer population health services like biometric screenings and flu shots, Quanum health IT solutions for data analytics and clinician connectivity, population health tools including Quest Lab Stewardship for test optimization and extended care services such as bone density exams and home collection kits, and pharmaceutical support encompassing clinical trials testing, companion diagnostics development, and Quest Clinical Trials Connect for patient recruitment. Operations span a nationwide network of full-service and rapid-response laboratories, over 2,000 patient service centers, mobile phlebotomists, and in-house experts providing consultation; the company serves one in three adult Americans and half of U.S. physicians and hospitals annually, with additional reach through the Global Diagnostic Network in countries including Puerto Rico, Mexico, Brazil, and Canada. Founded in 1967 as Metropolitan Pathology Laboratory in New York City and headquartered in Secaucus, New Jersey, Quest Diagnostics spun off from Corning in 1996 as an independent public company and employs nearly 50,000 people. It targets physicians, hospitals, employers, health plans, integrated delivery networks, and pharmaceutical firms across segments like general clinical testing, esoteric and gene-based assays, wellness services, and advanced diagnostics for chronic and infectious diseases. Recent developments include the 2023 acquisition of Haystack Oncology to integrate sensitive minimal-residual disease (MRD) liquid biopsy technology for solid tumor cancer detection into its portfolio, with services launching in 2024; the acquisition of select assets from Steward Health Care's outreach lab services in early 2024 to expand access; the May 2024 agreement to acquire PathAI Diagnostics, enhancing AI-powered digital pathology capabilities for faster cancer diagnosis, quality improvement, and extension into dermatopathology, gastrointestinal, and urological areas; and the 2024 announcement to acquire LifeLabs, Canada's leading diagnostics provider, from OMERS Infrastructure to broaden North American operations and advanced testing access. In 2022, the company acquired Pack Health to bolster patient engagement services for pharma clients and population health, alongside collaborations like retinal imaging with IRIS for diabetic retinopathy screening. These moves strengthen Quest's leadership in oncology, AI innovation, and geographic expansion amid a focus on data-driven insights and preventive care.
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year?
Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report?
Quest Diagnostics Declares Quarterly Cash Dividend
Is This the Right Time to Hold DGX Stock in Your Portfolio?
Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch
Bullish Quarterly Results: 3 Companies Raising Guidance
Quest Diagnostics: Updating Levels After Q1 Earnings
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Quest Diagnostics Prices $500 Million of Senior Notes
AEGON ASSET MANAGEMENT UK Plc Decreases Stake in Quest Diagnostics Incorporated $DGX
Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely
Quest Diagnostics Incorporated $DGX Stock Holdings Decreased by Cwm LLC
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings
Is Quest Diagnostics Inc (DGX) Overvalued After 4.5% Rally? GF Value Says Overvalued
Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript
Quest Diagnostics' Q1 Earnings & Revenues Top Estimates, Stock Up
Quest Diagnostics (DGX) Q1 Earnings and Revenues Top Estimates